StockData

PureTech Health plc (PTCHF) stock

PTCHFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as PRTCY
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 29, 2026Score 2/30
$1.48+0.00 (0.00%)

Close on Oct 19, 2026Market cap –P/E –Yield –

Earnings

PureTech Health's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
Issued
Aug 28, 2024 · 1 item

Quarterly results

Revenue and earnings per share from each of PureTech Health's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2025ended Dec 31, 2025Apr 29, 2026before the open–––Release
Q4 FY2024ended Dec 31, 2024Apr 30, 2025before the open–––Release
Q2 FY2024ended Jun 30, 2024Aug 28, 2024before the open–––Release
Q4 FY2023ended Dec 31, 2023Apr 25, 2024before the open–––Release
Q4 FY2022ended Dec 31, 2022Apr 28, 2023before the open–––Release
Q4 FY2021ended Dec 31, 2021Apr 26, 2022before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period PureTech Health guided for has been reported

Guidance history

Every forecast PureTech Health put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 28, 2024PureTech Level Cash, cash equivalents and short-term investmentsFY2024$330.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases PureTech Health filed with the SEC as exhibits to Form 8-K or 6-K

  1. PureTech Founded Entity Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering
    6-K
  2. PureTech Announces Annual Results for Year Ended December 31, 2025
    6-K
  3. PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London
    6-K
  4. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/2014) AS IT FORMS PART
    6-K
  5. Results of Annual General Meeting on June 16, 2025 – Update Statement
    6-K
  6. PureTech Health plc – Half-Year Report
    6-K
  7. Interim Management Report and Financial Review
    6-K
  8. Condensed Consolidated Statement of Comprehensive Income/(Loss) (Unaudited)
    6-K
  9. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/2014) AS IT FORMS PART
    6-K
  10. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/2014) AS IT FORMS PART
    6-K
  11. Results of Annual General Meeting
    6-K
  12. PureTech Announces Annual Results for Year Ended December 31, 2024
    6-K
  13. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE
    6-K
  14. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/ 2014) AS IT FORMS PART
    6-K
  15. PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round
    6-K

See a number that looks wrong?